Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION FILES NEW DRUG APPLICATION FOR AGRELIN WITH FDA

 EATONTOWN, N.J., Jan. 5 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has filed a New Drug Application (NDA) for AGRELIN(R) (anagrelide), a drug used to treat myeloproliferative disorders, serious diseases characterized by abnormally high platelet counts.
 Platelets are small cellular elements formed in the bone marrow and circulated throughout the body and are one of the body's first lines of defense against bleeding. When platelet counts are elevated, blood clots occur. When these clots block or significantly reduce the supply of blood to the heart or brain, a heart attack (myocardial infarction) or stroke is the end result.
 AGRELIN has been the subject of over five years of clinical trials in leading North American and European hematology or cancer centers, involving over 1000 patients. Recently, the results on one of the larger clinical trials, spearheaded by The Mayo Clinic, were published in The American Journal of Medicine.
 "AGRELIN is a lifesaving drug," said Roberts President and Chairman, Dr. Robert A. Vukovich." "Not only does it reduce seriously elevated platelet levels to normal or near normal levels, but the therapeutic benefit of this drug is due to its ability to reduce the morbidity and mortality associated with thromboembolic episodes," he continued. "AGRELIN should only be used in cases where platelet levels are significantly elevated. AGRELIN is not intended to be used in patients with normal platelet counts," he added.
 Roberts also announced today that it has filed a treatment IND with the Drugs Directorate, Health Protection Branch, in Ottowa, Ontario for AGRELIN. Upon approval by the Canadian drug regulatory authorities, Roberts Pharmaceutical of Canada, Inc., Roberts Canadian subsidiary, will be permitted to sell the product for emergency use. A New Drug Submission for Canada is planned for 1993.
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the United States, Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 1/5/93
 /CONTACT: Anthony P. Maris of Roberts Pharmaceutical Corporation, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:

LR-OS -- NY037 -- 1692 01/05/93 11:27 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 5, 1993
Words:405
Previous Article:INTERMAGNETICS ANNOUNCES INCREASE IN ULTRALIFE INVESTMENT
Next Article:BURLINGTON COAT FACTORY REPORTS RECORD SECOND FISCAL QUARTER AND DECEMBER NET SALES
Topics:


Related Articles
ROBERTS ANNOUNCES CLINICAL TRIAL RESULTS FOR AGRELIN IN THROMBOCYTOSIS
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN REGULATORY APPROVAL FOR AGRELIN(R) TREATMENT IND
ROBERTS PHARMACEUTICAL SUBMITS NEW DRUG APPLICATION TO FDA FOR URINARY INCONTINENCE DRUG
ROBERTS PHARMACEUTICAL CORPORATION DRUG TO RECEIVE HIGH-PRIORITY EC REGULATORY REVIEW
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES ITS AGRELIN NEW DRUG APPLICATION HAS BEEN ACCEPTED FOR FILING BY FDA
ROBERTS PHARMACEUTICAL CORPORATION INFORMED THAT ADDITIONAL INFORMATION IS REQUIRED WITH REGARD TO ITS NEW DRUG APPLICATION FOR PROAMATINE
ROBERTS PHARMACEUTICAL CORPORATION AND FDA TO MEET TO DISCUSS ACCELERATED APPROVAL OF PROAMATINE
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES FDA TO APPROVE THE COMPANY'S FIRST PIPELINE DRUG, PROAMATINE, UNDER THE ACCELERATED PROCESS
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES APPROVABLE LETTER AND PREPARES FOR U.S. LAUNCH OF PROAMATINE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters